Mutations in the epidermal growth factor receptor (EGFR) gene are established therapeutic targets within lung cancer treatment paradigms, with an overall somatic mutation rate of 30.6% in the Chinese NSCLC population [4, 5]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.